In a small clinic in Eswatini's Hhohho region, a sex worker named Thandiwe learned about lenacapavir—a revolutionary HIV prevention drug administered just twice a year—only to be turned away because stocks had run dry. Her story captures the cruel irony gripping the world's most burdened nation: Eswatini, where one in four people live with HIV, finally has access to a medication that could stop new infections in their tracks, yet supply constraints mean it remains out of reach for the very communities drowning in the epidemic.
The significance of lenacapavir cannot be overstated. This injectable antiretroviral, developed by Gilead Sciences, offers near-perfect protection against HIV transmission when taken as prescribed—efficacy rates above 99 percent in clinical trials. For a country where HIV prevalence stands at 27 percent among adults, the highest anywhere in the world, the arrival of lenacapavir in 2023 felt like a lifeline. Yet two years later, doses remain scarce, rationed among a tiny fraction of Eswatini's 1.2 million people, with fewer than 500 people estimated to have received the drug so far.
Eswatini's HIV epidemic is concentrated among its most vulnerable populations. Sex workers face infection rates of 70 percent or higher, while young women aged 15 to 24 account for a disproportionate share of new infections. These are precisely the people lenacapavir could protect, yet supply shortages mean clinics must choose between patients. Some facilities have stopped enrolling new people onto the drug altogether. "It's no more than a drop in the ocean," one health worker told researchers, describing the trickle of doses available against the scale of need.
The bottleneck isn't mysterious. Global manufacturing capacity for lenacapavir remains limited, with Gilead unable to produce enough to meet demand across multiple continents. Eswatini's orders have been partially fulfilled, leaving the country rationing a drug that could transform the trajectory of its epidemic. Meanwhile, other nations with far lower HIV burdens have secured larger allocations. Advocacy organizations argue that intellectual property barriers and inadequate technology transfer agreements have prevented generic manufacturers from scaling up production, keeping prices artificially high and supply artificially low.
For Eswatini, the timing compounds the tragedy. The country has made remarkable strides in recent years, expanding antiretroviral treatment to 95 percent of people living with HIV. Yet that success has masked an ongoing crisis: new infections continue at rates far above what would eliminate the epidemic. Lenacapavir could change that trajectory, breaking the cycle of transmission that has defined Eswatini's health landscape for decades. But only if it reaches the people who need it most.
Eswatini's government has begun negotiating directly with manufacturers to increase allocations, and international health organizations are advocating for prioritizing the nation's most vulnerable populations. Some progress is underway—the government recently launched a program specifically targeting sex workers in informal settlements. Yet those involved acknowledge the harsh mathematics: with current supply, it will take years to reach even half of those who could benefit. For Thandiwe and thousands like her, a drug that exists and works remains stubbornly out of reach, a measure of how the world's crisis of inequality plays out in real time.